Product Description
Description
Galliprant (grapiprant tablets) is indicated for the control of pain and inflammation associated with osteoarthritis in dogs. See package insert for complete product details.
Galliprant (grapiprant tablets) is a new, targeted approach to relieving canine osteoarthritis (OA) pain and inflammation. Its mode of action specifically targets the EP4 receptor, helping to keep the GI, kidney and liver homeostatic functions maintained.
Galliprant®(grapiprant tablets) is a new class of anti-inflammatory that targets pain, so you can start targeted pain relief from the earliest diagnosed stages of canine OA. Give these dogs the relief they need and help keep them doing the things they love.
- Galliprant is a first-in-class piprant; a non-COX-inhibiting prostaglandin receptor antagonist (PRA)
- Galliprant does not inhibit the production of many housekeeping prostanoids that maintain homeostatic functions1
- It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation1
Galliprant tested at up to approximately 15X the labeled dose for 9 months in healthy dogs.2,3
- Studied at up to approximately 15X the labeled 2 mg/kg dose for a 9-month duration in healthy dogs
- No clinically significant changes in liver, kidney or coagulation parameters
- No noticeable effects on food consumption, body weight, ECG, organ weight or hematology
- In most situations, gastrointestinal disturbances were mild or slight and fairly infrequent
- Neither treatment nor GI disturbance was associated with changes in appetite, appearance or demeanor of dogs
- Suitable for dogs as young as 9 months of age
Galliprant treatment resulted in statistically significant improvements in pain interference and pain severity scores compared to placebo on days 7, 14, 21 and 28.4
- Prospective, randomized, masked, placebo-controlled, 16-site study
- Galliprant dosed at 2 mg/kg once daily for 28 days
- 285 dogs enrolled
- Dogs receiving Galliprant were 2 to 16.75 years old, weighing 9 to 131 pounds
- Placebo tablet size and shape matched to Galliprant tablets
- Validated owner assessment: Canine Brief Pain Inventory (CBPI)* on days 0, 7, 14, 21, 28
- Veterinary assessment (total orthopedic scores) at screening and on days 14 and 28
Grapiprant represents a promising treatment modality for the pain and inflammation associated with OA in dogs.
Mode of action targets canine OA pain and inflammation while reducing the impact on GI, kidney and liver homeostasis1,2
- Suitable for dogs as young as 9 months of age
- Proven safe in a 9-month safety study at up to approximately 15X the recommended therapeutic dose in healthy dogs2,3
- Most dogs can be dosed with a whole or half tablet